Alopecia Clinical Trials in New York, New York
10 recruitingNew York, New York
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia Areata
AbbVie1,500 enrolled271 locationsNCT06012240
Recruiting
Phase 2
Deucravacitinib in the Treatment of Cicatricial Alopecias
Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia
Icahn School of Medicine at Mount Sinai20 enrolled1 locationNCT07508488
Recruiting
Phase 2
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Central Centrifugal Cicatricial AlopeciaLichen Planopilaris
Icahn School of Medicine at Mount Sinai30 enrolled1 locationNCT07487948
Recruiting
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Alopecia Areata
Pfizer300 enrolled1 locationNCT07226531
Recruiting
Phase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
Pfizer225 enrolled80 locationsNCT07029711
Recruiting
Phase 2
Dupilumab in the Treatment of Pediatric Alopecia Areata
Alopecia Areata
Icahn School of Medicine at Mount Sinai76 enrolled5 locationsNCT05866562
Recruiting
Phase 2
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Alopecia AreataAtopic Dermatitis
Icahn School of Medicine at Mount Sinai56 enrolled1 locationNCT07242638
Recruiting
Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Androgenetic alopecia (AGA)Hair LossAGA+2 more
Veradermics, Inc.552 enrolled71 locationsNCT07146022
Recruiting
Phase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Alopecia Areata
Pfizer550 enrolled114 locationsNCT06873945
Recruiting
Phase 2
Regeneron AA Multicenter (Dupilumab)
Alopecia Areata
Emma Guttman68 enrolled3 locationsNCT05551793